[1] 甘龙禹,李治国,郝文成,等.非侵入性诊断肝纤维化模型研究进展.肝脏,2018,23:83-86.
[2] Yan L, Deng Y, Zhou J, et al. Serum YKL-40 as a biomarker for liver fibrosis in chronic hepatitis B patients with normal and mildly elevated ALT. Infection, 2018,46:385-393.
[3] Hassoun E, Safrin M, Ziv H, et al. Procollagen C-Proteinase Enhancer 1 (PCPE-1) as a plasma marker of muscle and liver fibrosis in mice. PLoS One, 2016,11:e0159606.
[4] 中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南(2015更新版). 中华传染病杂志, 2015,33:915-932.
[5] 杨晴,刘东屏,李鲁平,等.慢性乙型肝炎肝纤维化非创伤性诊断模型的建立与评价.中华肝脏病杂志,2017,25:15-20.
[6] 赵秀华,荆燕,朱成宝,等.血清YKL-40和AFP联合检测对肝细胞癌患者手术预后判断的价值.中国肝脏病杂志(电子版),2017,9:61-67.
[7] 于瑞淼.探讨YKL-40在肝硬变中的诊断价值及其与肝硬变患者肝功能和现有肝纤维化指标的相关性.西北国防医学杂志,2017,38:579-582.
[8] Hassoun E, Safrin M, Wineman E, et al. Data comparing the plasma levels of procollagen C-proteinase enhancer 1 (PCPE-1) in healthy individuals and liver fibrosis patients. Data in Brief, 2017, 14:777-781.
[9] 俞冲,李民,顾玉玲,等.APRI、FIB-4及Fibro Touch联合检测对乙肝肝纤维化的早期预警价值.肝脏,2018,23:22-25. |
